NCT05216835 - Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

August 30, 2024

Study Completion Date

September 4, 2025

Conditions

Relapsed or Refractory Classical Hodgkin Lymphoma

Interventions

DRUG

Sabestomig (AZD7789)

Patients will receive sabestomig (PD-1/TIM-3 bispecific monoclonal antibody) via intravenous infusion.

Trial Locations (14)

Research Site, København Ø

Research Site, New York

Research Site, Miami

Research Site, Bologna

Research Site, Valencia

Research Site, Rochester

Research Site, Lille

Research Site, Houston

Research Site, Napoli

Research Site, Duarte

Research Site, Toronto

Research Site, Montreal

Research Site, Manchester

Research Site, Oxford